WO2016136633A1 - 脱細胞化組織 - Google Patents
脱細胞化組織 Download PDFInfo
- Publication number
- WO2016136633A1 WO2016136633A1 PCT/JP2016/054911 JP2016054911W WO2016136633A1 WO 2016136633 A1 WO2016136633 A1 WO 2016136633A1 JP 2016054911 W JP2016054911 W JP 2016054911W WO 2016136633 A1 WO2016136633 A1 WO 2016136633A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- decellularized
- decellularized tissue
- ratio
- mass
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Definitions
- the present invention relates to a decellularized tissue useful for regenerative medicine.
- the degree of decellularization can be determined by the content of DNA in the decellularized tissue, and it is known that the smaller the DNA content in the decellularized tissue, the less likely the rejection reaction occurs (for example, non-patented Reference 1).
- a method for decellularizing a living tissue a method using a surfactant (for example, see Patent Documents 1 and 2), a method using an enzyme (for example, see Patent Document 3), an oxidizing agent, and the like.
- Patent Document 4 Method used (for example, see Patent Document 4), method by high hydrostatic pressure treatment (for example, see Patent Documents 5 to 7), method by freeze-thaw treatment (for example, see Patent Documents 8 to 9), hypertonic electrolyte
- Patent Document 10 Method used (for example, see Patent Document 4), method by high hydrostatic pressure treatment (for example, see Patent Documents 5 to 7), method by freeze-thaw treatment (for example, see Patent Documents 8 to 9), hypertonic electrolyte
- Patent Document 10 A method of treating with a solution (see, for example, Patent Document 10) is known.
- JP-A-60-501540 Special table 2003-518981 gazette Japanese translation of PCT publication No. 2002-507907 Special table 2003-52562 gazette Japanese Patent Laid-Open No. 2004-094552 International Publication No. 2008/111530 Pamphlet Special table 2013-502275 gazette JP-A-2005-185507 JP 2005-21480 A JP 2010-2221012 A
- tissue regeneration When using a decellularized tissue in regenerative medicine, in addition to not having a rejection reaction, whether or not tissue regeneration can be performed quickly becomes a problem.
- Decellularized tissue obtained from biological tissue derived from the same organism even if it is a decellularized tissue from which cells have been removed to the same extent, if the decellularization method and procedure are different There may be differences in the rate of adhesion of host cells to decellularized tissue, the attractiveness of host cells, infiltration of host cells into decellularized tissue, etc., greatly affecting tissue regeneration .
- the present invention has been made to solve the above-described problems, and an object of the present invention is to provide a decellularized tissue excellent in cell adhesion.
- the present inventors have used a decellularized tissue with little change in endotherm in differential scanning calorimetry before and after decellularization of a living tissue.
- the present invention has been completed by finding that it can be quickly reproduced. Specifically, the present invention provides the following.
- a decellularized tissue obtained by decellularizing a living tissue A decellularized tissue, wherein a ratio of an endothermic amount per dry mass of a decellularized tissue with respect to a tissue derived from a living body before decellularization measured by differential scanning calorimetry is 0.70 or more.
- a decellularized tissue excellent in cell adhesion is provided.
- the decellularized tissue is expected to have a low cytotoxicity, a cell attracting effect and a differentiation inducing effect, and a high tissue regeneration effect.
- the decellularized tissue of the present invention is characterized in that the endothermic amount measured by differential scanning calorimetry is not changed much compared to the tissue before decellularization.
- the endothermic amount measured by differential scanning calorimetry is referred to as “DSC endothermic amount”.
- DSC endothermic amount the endothermic amount measured by differential scanning calorimetry
- endotherm is observed in the region of 55 to 70 ° C.
- decellularized endothermic ratio The ratio of the endothermic amount per dry mass, measured by differential scanning calorimetry, of the decellularized tissue with respect to the biological tissue before decellularization.
- the mass ratio of the amount of DNA per dry mass of the decellularized tissue to the tissue derived from the living body before decellularization is referred to as “decellularized DNA ratio”.
- decellularized DNA ratio the mass ratio of the amount of DNA per dry mass of the decellularized tissue to the tissue derived from the living body before decellularization.
- both the decellularized DNA ratio and the decellularized endothermic ratio It is based on the dry mass of the living tissue and its decellularized tissue.
- the decellularized endothermic ratio of the decellularized tissue of the present invention is 0.70 or more, and when the decellularized endothermic ratio is lower than 0.70, cell attraction to the decellularized tissue or Cell differentiation induction is not sufficient, and regenerative treatment with decellularized tissue may be adversely affected.
- the decellularization endothermic ratio is preferably 0.72 or more, more preferably 0.74 or more, and most preferably 0.77 or more. It is preferable that the decellularized endothermic ratio is 0.77 or more because cell adhesion to a decellularized tissue is particularly easily enhanced.
- the upper limit value of the decellularized endothermic ratio is not particularly limited, but when it is 1.3 or less, preferably 1.27 or less, more preferably 1.25 or less, and most preferably 1.23 or less, the decellularized tissue This is preferable in that cell attractability and cell differentiation induction are likely to be favorable.
- the decellularized endothermic ratio When calculating the decellularized endothermic ratio, after performing differential scanning calorimetry, the dry mass of the sample used for the measurement is measured, the DSC endothermic amount per dry mass is calculated, and before decellularization The decellularized endothermic ratio may be calculated from the DSC endothermic amount per dry mass of the decellularized tissue with respect to the DSC endothermic amount per dry mass of the tissue. “Drying the sample” means drying the sample until the water content in the sample becomes 5% by mass or less. The means for drying the sample is not particularly limited, and examples include the method performed in Examples.
- the present inventors assumed that the cell attracting effect and differentiation inducing effect of the decellularized tissue correlate with the collagen content of the decellularized tissue, but there is not necessarily a correlation, and the collagen content is There is a decellularized tissue that has a low cell attracting effect and a low differentiation inducing effect even if it is high, a cell adhesion property of the decellularized tissue, a cell attracting effect, a differentiation inducing effect, and a DSC endothermic amount of the decellularized tissue We found that there can be a correlation between
- collagen in living tissue has a triple helical structure called a collagen helix.
- the present inventors show that the endotherm in the region of 55 to 70 ° C. of living tissue or decellularized tissue is due to the cleavage of hydrogen bond between collagen and collagen or collagen and coordination water of collagen having a triple helical structure. Therefore, it is presumed that the DSC endothermic amount of the decellularized tissue correlates with the content of collagen having a triple helical structure, not the collagen content of the decellularized tissue. Furthermore, the present inventors presume that a decellularized tissue having a triple-helical structure and a higher collagen content, which has a structure similar to that of collagen in living tissue, has a higher cell attracting effect and differentiation inducing effect. Yes.
- the decellularized tissue has a low DNA content.
- the decellularized DNA ratio is preferably 0.300 or less.
- the decellularized DNA ratio of the decellularized tissue of the present invention is preferably 0.200 or less, more preferably 0.150 or less, most preferably 0.080 or less, 0.005 or less is particularly preferable. It is preferable that the decellularized DNA ratio is 0.080 or less because cell adhesion to a decellularized tissue is particularly easy to improve.
- the lower limit of the decellularized DNA ratio is preferably as low as possible, and is preferably 0.001 or more, more preferably 0.002 or more for ease of realization.
- the biological tissue used for the decellularized tissue of the present invention is not particularly limited as long as it is a vertebrate-derived biological tissue. However, since there are few rejection reactions, a biological tissue derived from mammals or birds is preferable and is easily available. In view of this, a living tissue derived from a mammal, a bird or a human is more preferable.
- Mammalian livestock includes cattle, horses, camels, llamas, donkeys, yaks, sheep, pigs, goats, deer, alpaca, dogs, raccoons, weasels, foxes, cats, rabbits, hamsters, guinea pigs, rats, mice, squirrels, Raccoon etc. are mentioned.
- avian livestock examples include parakeets, parrots, chickens, ducks, turkeys, geese, guinea fowls, pheasants, ostriches, quails, and emu.
- bovine, porcine, rabbit, and human biological tissues are preferable from the viewpoint of availability.
- a part having a matrix structure outside the cell can be used, and as such a part, for example, liver, kidney, ureter, bladder, urethra, tongue, tonsils, esophagus, stomach, small intestine, Examples include large intestine, anus, pancreas, heart, blood vessel, spleen, lung, brain, bone, spinal cord, cartilage, testis, uterus, fallopian tube, ovary, placenta, cornea, skeletal muscle, tendon, nerve, skin and the like.
- cartilage, bone, liver, kidney, heart, pericardium, blood vessel, skin, small intestine submucosa, lung, brain, and spinal cord are preferable because of the high tissue regeneration effect.
- the method for obtaining the decellularized tissue of the present invention is not particularly limited as long as it is a decellularization method in which the decellularized endothermic ratio is 0.7 to 1.3.
- Preferred methods for obtaining the decellularized tissue of the present invention include, for example, a method by high hydrostatic pressure treatment, a method by freeze-thaw treatment, etc., and it is easy to lower the decellularized DNA ratio.
- a method by high hydrostatic pressure treatment is preferred.
- the high hydrostatic pressure treatment of the biological tissue is preferably performed in a cleaning solution containing a surfactant.
- the content of the surfactant varies depending on the biological tissue to be washed and the type of the surfactant, but is preferably 0.01% by mass or more and 2.00% by mass or less, and 0.03% by mass or more and 1. 00 mass% or less is still more preferable, 0.05 mass% or more and 0.50 mass% or less are the most preferable.
- a nucleolytic enzyme and a surfactant are used for washing a tissue derived from a living body to which a high hydrostatic pressure is applied, the washing effect can be improved. If a nucleolytic enzyme is used after using a cleaning solution containing a surfactant, the cleaning effect can be further increased.
- a hydrostatic pressure of 50 to 1500 MPa is applied to the living body-derived tissue in a medium.
- the applied hydrostatic pressure is lower than 50 MPa, decellularization may be insufficient, and damage to the tissue in the process of washing with a washing solution containing a surfactant after high hydrostatic pressure treatment is increased.
- the pressure exceeds 1500 MPa, a pressure vessel that can withstand application is required, and enormous energy is required.
- the medium used for application is an aqueous medium, ice is generated, and the tissue is damaged by the generated ice.
- the applied hydrostatic pressure is preferably 80 to 1300 MPa, more preferably 90 to 1200 MPa, and most preferably 95 to 1100 MPa.
- Examples of the medium used for applying the hydrostatic pressure include water, physiological saline, propylene glycol or an aqueous solution thereof, glycerin or an aqueous solution thereof, and an aqueous saccharide solution.
- Examples of the buffer solution include acetate buffer solution, phosphate buffer solution, citrate buffer solution, borate buffer solution, tartaric acid buffer solution, Tris buffer solution, HEPES buffer solution, MES buffer solution and the like.
- saccharide in the aqueous saccharide solution examples include erythrose, xylose, arabinose, allose, talose, glucose, mannose, galactose, erythritol, xylitol, mannitol, sorbitol, galactitol, sucrose, lactose, maltose, trehalose, dextran, alginic acid, hyaluronic acid, etc. Can be mentioned.
- the temperature of the high hydrostatic pressure treatment is not particularly limited as long as no ice is generated and the tissue is not damaged by heat, but it is 0 to 0 because the decellularization treatment is performed smoothly and the tissue is less affected. 45 ° C is preferable, 4-37 ° C is more preferable, and 15-35 ° C is most preferable. If the time for the high hydrostatic pressure treatment is too short, cells are not sufficiently destroyed, and if it is long, energy is wasted. Therefore, the time for maintaining the target applied pressure in the high hydrostatic pressure treatment is 5 to 60 minutes is preferable, and 7 to 30 minutes is more preferable.
- the cleaning liquid may be the same as or different from the medium for the high hydrostatic pressure treatment.
- the cleaning liquid preferably contains a nucleolytic enzyme, an organic solvent, or a chelating agent. Nucleolytic enzymes can improve the removal efficiency of nucleic acid components from living tissues to which hydrostatic pressure is applied, organic solvents are lipids, and chelating agents can reduce calcium ions and magnesium ions in decellularized tissues. By inactivation, calcification when the particulate decellularized tissue of the present invention is applied to a diseased part can be prevented.
- a water-soluble organic solvent is preferable because it has a high effect of removing lipids, and ethanol, isopropanol, acetone, and dimethyl sulfoxide are preferable.
- Chelating agents include ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), diethylenetriminepentaacetic acid (DTPA), hydroxyethylethylenediaminetriacetic acid (HEDTA), triethylenetetraminehexaacetic acid (TTHA), 1,3-propane Diamine tetraacetic acid (PDTA), 1,3-diamino-2-hydroxypropanetetraacetic acid (DPTA-OH), hydroxyethyliminodiacetic acid (HIDA), dihydroxyethylglycine (DHEG), glycol ether diamine tetraacetic acid (GEDTA), Iminocarboxylic acid-based chelating agents such as dicarboxymethylglutamic acid (
- the cleaning liquid may contain a surfactant.
- Surfactants include fatty acid soap, alkoxy carboxylate, polyoxyethylene alkoxy carboxylate, alkyl sulfonate, alkyl benzene sulfonate, alkyl sulfate ester salt, polyoxyethylene alkyl sulfate ester salt, alkyl phosphoric acid Anionic surfactants such as ester salts, ⁇ -sulfo fatty acid ester salts, N-acyl glutamate salts, acyl-N-methyl taurate salts, N-alkyl sarcosine salts, cholate salts, deoxycholate salts;
- Cationic surfactants such as alkyldimethylamine, alkyldiethanolamine, alkyltrimethylammonium salt, dialkyldimethylammonium salt, alkylpyridium salt, alkylbenzyldimethylammonium salt;
- Glycerin fatty acid ester sorbitan fatty acid ester, sucrose fatty acid ester, trehalose fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene alkylphenyl ether, poly Oxyethylene polyoxypropylene ether, alkyl (poly) glycerin ether, fatty acid alkanolamide, polyoxyethylene fatty acid alkanolamide, alkyl (poly) glycoside, alkylmaltoside, alkylthioglucoside, alkylmaltopyranoside, alkanoyl-N-methyl- D-glucosamine, N, N-bis (3-D-gluconamidopropyl) coleamide (B GCHAP), N, N- bis (3-D-gluconic acid amidopropyl) deoxycholic amide (the deoxy-B
- Surfactants include alkyl sulfonates, alkyl sulfate esters, polyoxyethylene alkyl sulfate esters, ⁇ -sulfo fatty acid ester salts, polyoxyethylene alkyl ethers, polyoxyethylene alkyl phenyl ethers in terms of cell removal.
- Alkyl (poly) glycosides are preferred, and alkyl sulfonates, polyoxyethylene alkyl ethers, polyoxyethylene alkyl phenyl ethers, and alkyl (poly) glycosides are more preferred.
- the temperature when washing a biological tissue to which a high hydrostatic pressure is applied is not particularly limited as long as it does not damage the tissue due to heat, but it is 0 to 0 because it has good detergency and little influence on the tissue. 45 ° C is preferable, 1 to 40 ° C is more preferable, and 2 to 35 ° C is most preferable.
- the washing solution may be shaken or stirred as necessary.
- the tissue derived from a living body is kept at a temperature of ⁇ 80 to ⁇ 20 ° C., preferably ⁇ 80 to ⁇ 40 ° C. for 1 to 48 hours, preferably 10 to
- the step of freezing by holding for 30 hours and then thawing at a temperature of 20 to 37 ° C. is repeated once or twice or more, preferably 2 to 5 times.
- the cleaning method may be the same method as the cleaning in the high hydrostatic pressure treatment.
- the measurement of the decellularized DNA ratio and the decellularized endothermic ratio is excellent as a method for selecting a decellularized tissue excellent in host cell attraction, adhesion, infiltration, etc.
- a step of confirming that the mass ratio of the amount of DNA per dry mass of the decellularized tissue to the living tissue before decellularization is 0.3 or less (that is, the decellularized DNA ratio is 0.3 or less)
- the ratio of the endothermic amount per dry mass, measured by differential scanning calorimetry, of the decellularized tissue relative to the biological tissue before decellularization is 0.7 to 1.3
- a step for confirming the existence that is, a step for confirming that the decellularization endothermic ratio is 0.7 to 1.3
- a good decellularized tissue can be obtained.
- the step of confirming that the decellularized DNA ratio is 0.3 or less and the step of confirming that the decellularized endothermic ratio is 0.7 to 1.3 are the steps of washing the decellularized tissue. It is preferably after, and when there is a step of sterilizing or sterilizing the decellularized tissue, it is preferably after the step of washing the decellularized tissue and before the step of sterilizing or sterilizing.
- the decellularized tissue of the present invention may be applied alone, or may be applied together with other components that have a regeneration / healing effect on a disease site.
- other components include growth factors, proteoglycans or glycosaminoglycans, cells, ⁇ -1,3-glucan, mevalonic acid and the like.
- Growth factors include insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), transforming growth factor- ⁇ (TGF- ⁇ ), transforming growth factor (TGF- ⁇ ), bone morphogenetic protein (BMP), platelet-derived growth factor (PDGF), keratinocyte growth factor (KGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), hematopoietic promoter ( EPO), granule macrophage growth factor (GM-CSF), granule cell growth factor (G-CSF), nerve cell growth factor (NGF), heparin binding (EGF) and the like.
- IGF insulin-like growth factor
- bFGF basic fibroblast growth factor
- aFGF acidic fibroblast growth factor
- TGF- ⁇ transforming growth factor- ⁇
- TGF- ⁇ transforming growth factor
- BMP bone morphogenetic protein
- PDGF platelet-derived growth factor
- KGF epi
- proteoglycan or glycosaminoglycan examples include chondroitin sulfate, heparan sulfate, keratan sulfate, dermatan sulfate, hyaluronic acid, heparin and the like.
- the decellularized tissue of the present invention may be used for transplantation as it is, or may be used after seeding and culturing cells.
- the decellularized tissue of the present invention may be cut, sliced, pulverized and processed into a sheet, granular, fine powder, gel or the like.
- the decellularized tissue is a sheet, May be used in combination with decellularized tissues or in combination with other sheet-like tissue, or may be processed into a tubular shape.
- a decellularized tissue having an excellent cell attracting effect is provided.
- the cell attracting effect of the decellularized tissue can be evaluated by subjecting the decellularized tissue to a cell adhesion test by the method described in the Examples.
- Example 1 A sheet-like intima (hereinafter referred to as “intimal sheet”) collected by cutting a porcine aorta into a bag with polyethylene chuck, and physiological saline as a medium for high hydrostatic pressure treatment Then, a hydrostatic pressure of 100 MPa was applied for 15 minutes using a high-pressure treatment apparatus for research and development (manufactured by Kobe Steel, trade name: Dr. CHEF). After washing the inner membrane sheet treated with high hydrostatic pressure in physiological saline containing 20 ppm DNase as a nucleolytic enzyme by shaking at 4 ° C. for 96 hours, and further shaking in 80% ethanol at 4 ° C. for 72 hours. The decellularized tissue of Example 1 was obtained by shaking in physiological saline at 4 ° C. for 2 hours.
- intimal sheet A sheet-like intima (hereinafter referred to as “intimal sheet”) collected by cutting a porcine aorta into a bag with polyethylene chuck, and physiological
- Example 2 In Example 1, a decellularized tissue of Example 2 was obtained by performing the same operation as in Example 1 except that the shaking time in physiological saline containing 20 ppm of DNase was changed from 96 hours to 8 hours.
- Example 3 The inner membrane sheet was frozen with dry ice, stored in a cold box (about ⁇ 78 ° C.) containing dry ice for 20 hours, and then melted at 25 ° C.
- the inner membrane sheet obtained by repeating this freeze-thaw three times was subjected to an enzyme treatment by shaking for 96 hours at 4 ° C. in physiological saline containing 20 ppm of DNase as a nucleolytic enzyme, and further 72% at 4 ° C. in 80% ethanol. After shaking for 4 hours, the cells were shaken in physiological saline at 4 ° C. for 2 hours to obtain the decellularized tissue of Example 3.
- Example 4 The inner membrane sheet was decellularized by shaking at 25 ° C. for 96 hours in physiological saline containing 0.1% by mass of sodium dodecylsulfonate (hereinafter, SDS). After the SDS-treated inner membrane sheet was shaken in physiological saline containing 20 ppm of DNase as a nucleolytic enzyme at 4 ° C. for 96 hours, and further shaken in 80% ethanol at 4 ° C. for 72 hours, The decellularized tissue of Example 4 was obtained by shaking in saline at 4 ° C. for 2 hours.
- SDS sodium dodecylsulfonate
- Example 5 In the same manner as in Example 1, a hydrostatic pressure of 1000 MPa was applied to the inner membrane sheet for 15 minutes.
- the inner membrane sheet subjected to high hydrostatic pressure treatment was shaken at 25 ° C. for 8 hours in physiological saline containing 0.1% by mass sodium dodecylsulfonate (hereinafter, SDS), and then contained 20 ppm of DNase as a nucleolytic enzyme. Washed by shaking in physiological saline at 25 ° C. for 24 hours. Furthermore, after shaking in 80% ethanol at 4 ° C. for 72 hours, it was shaken in physiological saline at 4 ° C. for 2 hours to obtain the decellularized tissue of Example 5.
- SDS sodium dodecylsulfonate
- Example 6 In Example 5, the decellularized tissue of Example 6 was obtained by performing the same operation as in Example 5 except that the hydrostatic pressure in the high hydrostatic pressure treatment was changed from 1000 MPa to 400 MPa.
- Example 7 the decellularized tissue of Example 6 was obtained by performing the same operation as in Example 5 except that the hydrostatic pressure in the high hydrostatic pressure treatment was changed from 1000 MPa to 600 MPa.
- Example 8 In Example 1, the decellularized tissue of Example 8 was obtained by performing the same operation as in Example 1 except that the hydrostatic pressure in the high hydrostatic pressure treatment was changed from 100 MPa to 600 MPa.
- Example 4 a decellularized tissue of Comparative Example 1 was obtained by performing the same operation as in Example 4 except that the concentration of SDS was changed from 0.1% by mass to 1% by mass.
- Example 4 the physiological saline containing 0.1% by mass of SDS was changed to a physiological saline containing 1% by mass of Triton X-100 (polyoxyethylene octylphenyl ether: hereinafter referred to as TX). The same operation as in Example 4 was performed to obtain a decellularized tissue of Comparative Example 2.
- Triton X-100 polyoxyethylene octylphenyl ether
- Comparative Example 3 In Comparative Example 2, a decellularized tissue of Comparative Example 3 was obtained by performing the same operation as Comparative Example 3 except that the TX concentration was changed from 1% by mass to 0.1% by mass.
- Comparative Example 4 The inner membrane sheet was subjected to ultrasonic treatment (intensity: 10 W / cm 2 , frequency: 10 kHz, action time: 2 minutes) in physiological saline. With respect to the ultrasonically treated inner membrane sheet, the same operation as in Comparative Example 2 was performed to obtain a decellularized tissue of Comparative Example 4.
- Comparative Example 5 In Comparative Example 4, a decellularized tissue of Comparative Example 5 was obtained by performing the same operation as Comparative Example 5 except that the TX concentration was changed from 1% by mass to 0.1% by mass.
- DNA content per dry mass of the test piece was calculated.
- the decellularized DNA ratio was calculated from the ratio of the DNA content of the dry test piece of the inner membrane sheet and the DNA content of the dry test piece of the decellularized tissue. The results are shown in Table 1.
- (Decellularized DNA ratio) (DNA content of dry test piece of decellularized tissue) / (DNA content of dry test piece of inner membrane sheet)
- the endothermic amounts of the living tissue before decellularization, the decellularized tissues of Examples 1 and 4 and the decellularized tissue of Comparative Example 2 are shown in FIGS.
- the sample pan after measuring the endotherm is punctured, stored in a thermostat at 60 ° C for 12 hours and dried, then the mass of the sample pan containing the dried test piece is measured, and tested according to the following formula The endothermic amount per dry mass of the piece was calculated.
- (Endothermic amount per dry mass of test piece) (Endothermic amount) / ⁇ (Mass of sample pan containing dried test piece) ⁇ (Mass of sample pan) ⁇
- Non-adherent cells were washed and removed from the test piece using phosphate buffered saline, and then the test piece was stained with Wst-8 (manufactured by Dojindo Laboratories), and the absorbance at 450 nm was measured. Separately, the number of NHDF and a calibration curve when stained with Wst-8 were prepared, and the number of NHDF adhering to the test piece was calculated from the absorbance of the test piece and the calibration curve. The results are shown in Table 1.
- Examples 9 to 12 show production examples of the decellularized tissue of the present invention for biological tissues other than the porcine aortic intimal sheet used in Examples 1 to 8 and Comparative Examples 1 to 6. Comparative production examples are shown in Comparative Examples 7 to 10. All of the decellularized tissues of Examples had a higher cell adhesion number than the decellularized tissues of Comparative Examples, and were excellent in the cell attracting effect.
- Example 9 In Example 8, the same operation as in Example 8 was performed except that the porcine aorta itself was used instead of the sheet-like intima (intimal sheet) collected by opening the porcine aorta. Decellularized tissue was obtained. The decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
- Example 10 In Example 8, the same operation as in Example 8 was performed except that porcine skin (including dermis) was used instead of the sheet-like intima (intimal sheet) collected by opening the porcine aorta.
- porcine skin including dermis
- the decellularized tissue of Example 10 was obtained.
- the decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
- Example 11 In Example 8, the same operation as in Example 8 was performed except that porcine pericardium was used instead of the sheet-like intima (intimal sheet) collected by cutting open the porcine aorta. Decellularized tissue was obtained. The decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
- Example 12 In Example 8, instead of the sheet-like intima (intimal sheet) collected by opening the porcine aorta, a sheet-like intima collected by opening the bovine aorta was used. The same operation was performed to obtain the decellularized tissue of Example 12. The decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
- Comparative Example 7 In Comparative Example 1, the same operation as in Comparative Example 1 was carried out except that the porcine aorta itself was used instead of the sheet-like intima (intimal sheet) collected by opening the porcine aorta. Decellularized tissue was obtained. The decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
- Comparative Example 8 In Comparative Example 1, the same operation as in Comparative Example 1 was performed except that porcine skin (including the dermis) was used instead of the sheet-like intima (intimal sheet) collected by opening the porcine aorta. The decellularized tissue of Comparative Example 8 was obtained. The decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
- Comparative Example 9 In Comparative Example 1, the same operation as in Comparative Example 1 was performed except that porcine pericardium was used instead of the sheet-like intima (intimal sheet) collected by opening the porcine aorta. Decellularized tissue was obtained. The decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
- Comparative Example 10 In Comparative Example 1, instead of the sheet-like intima (intimal sheet) collected by opening the porcine aorta, a sheet-like intima collected by opening the bovine aorta was used, and Comparative Example 1 and The same operation was performed to obtain a decellularized tissue of Comparative Example 10. The decellularized DNA ratio and the decellularized endothermic ratio of the obtained decellularized tissue were calculated by the above method. The results are shown in Table 2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
脱細胞化前の生体由来組織に対する脱細胞化組織の、示差走査熱量測定により測定される、乾燥質量あたりの吸熱量の比が0.70以上であることを特徴とする脱細胞化組織。
本発明の脱細胞化組織の脱細胞化吸熱量比は、0.70以上であり、脱細胞化吸熱量比が0.70よりも低い場合には、脱細胞化組織への細胞誘引性や細胞の分化誘導性が十分ではなく、脱細胞化組織による再生治療に悪影響がでる場合がある。脱細胞化吸熱量比は0.72以上が好ましく、0.74以上が更に好ましく、0.77以上が最も好ましい。脱細胞化吸熱量比が0.77以上であると、脱細胞化組織への細胞接着性を特に高めやすい点で好ましい。
(乾燥質量あたりのDSC吸熱量)=(未乾燥試料のDSC吸熱量)×(乾燥後の試料の質量/(乾燥前の試料の質量))
(脱細胞化吸熱量比)=(脱細胞化組織の乾燥質量あたりのDSC吸熱量)/(脱細胞化前の組織の乾燥質量あたりのDSC吸熱量)
一般に脱細胞化組織のDNA含量は少ないことが好ましいとされているが、本発明の脱細胞化組織では、脱細胞化DNA比は、0.300以下であることが好ましい。脱細胞化DNA比が0.300を超える場合は、再生医療に使用した場合に拒絶反応が発生する場合がある。細胞の誘引効果や分化誘導効果の点から、本発明の脱細胞化組織の脱細胞化DNA比は、0.200以下が好ましく、0.150以下が更に好ましく、0.080以下が最も好ましく、0.005以下が特に好ましい。脱細胞化DNA比が0.080以下であると、脱細胞化組織への細胞接着性を特に高めやすい点で好ましい。
(脱細胞化DNA比)=(乾燥した脱細胞化組織のDNA含量)/(乾燥した脱細胞化前の組織のDNA含量)
(乾燥減量比)=(乾燥後の質量)/(乾燥前の質量)
(乾燥した組織のDNA含量)=(未乾燥の組織のDNA含量)/(乾燥減量比)
本発明の脱細胞化組織に使用する生体組織は、脊椎動物由来の生体組織であれば、特に限定されないが、拒絶反応が少ないことから、哺乳類又は鳥類由来の生体組織が好ましく、入手が容易であることから、哺乳類の家畜、鳥類の家畜又はヒト由来の生体組織が更に好ましい。哺乳類の家畜としては、ウシ、ウマ、ラクダ、リャマ、ロバ、ヤク、ヒツジ、ブタ、ヤギ、シカ、アルパカ、イヌ、タヌキ、イタチ、キツネ、ネコ、ウサギ、ハムスター、モルモット、ラット、マウス、リス、アライグマ等が挙げられる。また、鳥類の家畜としては、インコ、オウム、ニワトリ、アヒル、七面鳥、ガチョウ、ホロホロ鳥、キジ、ダチョウ、ウズラ、エミュー等が挙げられる。これらの中でも、入手の安定性から、ウシ、ブタ、ウサギ、ヒトの生体組織が好ましい。
本発明の脱細胞化組織を得る方法は、脱細胞化吸熱量比が0.7~1.3となる脱細胞化方法であれば、特に限定されない。
ポリエチレン製チャック付き袋に、ブタの大動脈を切り開いて採取したシート状の内膜(以下、該シート状の内膜を「内膜シート」という。)と、高静水圧処理の媒体として生理食塩水と、を入れ、研究開発用高圧処理装置(神戸製鋼製、商品名:Dr.CHEF)を用いて、100MPaの静水圧を15分間印加した。高静水圧処理した内膜シートを、核酸分解酵素としてDNaseを20ppm含有する生理食塩水中、4℃で96時間振盪することにより洗浄し、更に、80%エタノール中、4℃で72時間振盪した後、生理食塩水中、4℃で2時間振盪して、実施例1の脱細胞化組織を得た。
実施例1において、DNaseを20ppm含有する生理食塩水中での振盪時間を96時間から8時間に変更した以外は実施例1と同様の操作を行い実施例2の脱細胞化組織を得た。
内膜シートを、ドライアイスで凍結させ、ドライアイスを入れた保冷箱中(約-78℃)で20時間保存した後、25℃で溶解させた。この凍結融解を3回繰り返した内膜シートを、核酸分解酵素としてDNaseを20ppm含有する生理食塩水中、4℃で96時間振盪することにより酵素処理し、更に、80%エタノール中、4℃で72時間振盪した後、生理食塩水中、4℃で2時間振盪して、実施例3の脱細胞化組織を得た。
内膜シートを、0.1質量%のドデシルスルホン酸ナトリウム(以下、SDS)を含有する生理食塩水中、25℃で96時間振盪することにより脱細胞した。SDS処理した内膜シートを、核酸分解酵素としてDNaseを20ppm含有する生理食塩水中、4℃で96時間振盪することにより酵素処理し、更に、80%エタノール中、4℃で72時間振盪した後、生理食塩水中、4℃で2時間振盪して、実施例4の脱細胞化組織を得た。
実施例1と同様の方法で、内膜シートに対し、1000MPaの静水圧を15分間印加した。高静水圧処理した内膜シートを、0.1質量%のドデシルスルホン酸ナトリウム(以下、SDS)を含有する生理食塩水中、25℃で8時間振盪し、次いで、核酸分解酵素としてDNaseを20ppm含有する生理食塩水中、25℃で24時間振盪することにより洗浄した。更に、80%エタノール中、4℃で72時間振盪した後、生理食塩水中、4℃で2時間振盪して、実施例5の脱細胞化組織を得た。
実施例5において、高静水圧処理の静水圧を1000MPaから400MPaに変更した以外は実施例5と同様の操作を行い実施例6の脱細胞化組織を得た。
実施例5において、高静水圧処理の静水圧を1000MPaから600MPaに変更した以外は実施例5と同様の操作を行い実施例6の脱細胞化組織を得た。
実施例1において、高静水圧処理の静水圧を100MPaから600MPaに変更した以外は実施例1と同様の操作を行い実施例8の脱細胞化組織を得た。
実施例4において、SDSの濃度を0.1質量%から、1質量%に変更した以外は実施例4と同様の操作を行い比較例1の脱細胞化組織を得た。
実施例4において、0.1質量%のSDSを含有する生理食塩水を1質量%のトリトンX-100(ポリオキシエチレンオクチルフェニルエーテル:以下、TX)を含有する生理食塩水に変更した以外は実施例4と同様の操作を行い比較例2の脱細胞化組織を得た。
比較例2において、TXの濃度を1質量%から、0.1質量%に変更した以外は比較例3と同様の操作を行い比較例3の脱細胞化組織を得た。
内膜シートを、生理食塩水中で、超音波処理(強度:10W/cm2 、周波数:10kHz、作用時間:2分間)した。超音波処理した内膜シートについて、比較例2と同様の操作を行い、比較例4の脱細胞化組織を得た。
比較例4において、TXの濃度を1質量%から、0.1質量%に変更した以外は比較例5と同様の操作を行い比較例5の脱細胞化組織を得た。
リン酸緩衝液に、CHAPS、塩化ナトリウム及びEDTAをそれぞれ、8mmol/L、1mol/L、25mmol/Lになるように添加した液を、脱細胞化液とした。内膜シートを、この脱細胞化液中、25℃で96時間振盪することにより脱細胞し、核酸分解酵素としてDNaseを20ppm含有する生理食塩水中、25℃で24時間振盪することにより酵素処理し、更に、80%エタノール中、4℃で72時間振盪した後、生理食塩水中、4℃で2時間振盪して、比較例6の脱細胞化組織を得た。
各脱細胞化組織の質量を測定し、これを試験片とし、タンパク質分解酵素溶液に浸漬して溶解した後、フェノール/クロロホルムで処理してタンパク質を除去し、エタノール沈殿法によりDNAを回収した。回収したDNAをピコグリーン(Life Technologies社)により蛍光染色して蛍光強度を測定することによりDNAを定量し、試験片の質量とDNAの量から、試験片のDNA含量を算出した。なお、DNAの定量には、ピコグリーンに添付された標準DNAを用いて作成した検量線を用いた。別の試験片を用いて、試験片の質量と乾燥した試験片(60℃の恒温槽に12時間保存したもの)の質量とから、乾燥減量比を求め、試験片のDNA含量と乾燥減量比から、試験片の乾燥質量あたりのDNA含量を算出した。
(試験片のDNA含量)=(DNAの量)/(試験片の質量)
(乾燥減量比)=(乾燥した試験片の質量)/(試験片の質量)
(乾燥試験片のDNA含量)=(試験片のDNA含量)/(乾燥減量比)
(脱細胞化DNA比)=(脱細胞化組織の乾燥試験片のDNA含量)/(内膜シートの乾燥試験片のDNA含量)
3mm×3mmに切断した試験片を、質量を測定したアルミ製の試料パンに入れ、示差走査熱量測定機(METTLER TOREDO社製、型式DSC1)を用い、測定開始温度25℃、昇温速度3℃/分、測定終了温度90℃の条件で示差走査熱量を測定した。55~68℃の領域にコラーゲン由来とみられる吸熱がみられることから、この吸熱量を試験片の吸熱量とした。脱細胞化前の生体由来組織、実施例1及び4の脱細胞化組織、比較例2の脱細胞化組織の吸熱量をそれぞれ図1~4に示す。吸熱量の測定後の試料パンは穴を開けて、60℃の恒温槽に12時間保存して乾燥させてから、乾燥した試験片が入った試料パンの質量を測定し、下記の式より試験片の乾燥質量あたりの吸熱量を算出した。
(試験片の乾燥質量あたりの吸熱量)=(吸熱量)/{(乾燥した試験片が入った試料パンの質量)-(試料パンの質量)}
(脱細胞化吸熱量比)=(脱細胞化組織の乾燥質量あたりの吸熱量)/(内膜シートの乾燥質量あたりの吸熱量)
実施例1~7又は比較例1~6の脱細胞化組織を、直径6mmの生検トレパンを用いて円盤状に切り抜いたものを試験片とした。円盤状試験片の内膜側を上にして96well plate dishに設置し、10%のウシ胎児血清(FBS)を含有するMEM培地で37℃で12時間、前培養した。MEM培地を除去した後、ヒト皮膚線維芽細胞(NHDF)を播種(2.7×103細胞/well)し、37℃で3時間培養した。試験片から、付着していない細胞をリン酸緩衝生理食塩水を用いて洗浄及び除去した後、試験片をWst-8(同人化学研究所製)で染色し、450nmでの吸光度を測定した。別途、NHDFの数と、Wst-8により染色した場合の検量線を作成しておき、試験片の吸光度と検量線から、試験片に付着したNHDF数を算出した。結果を表1に示す。
実施例1~8、比較例1~6で使用したブタ大動脈内膜シート以外の生体組織について、本発明の脱細胞化組織の製造例を実施例9~12に示す。また比較の製造例を比較例7~10に示す。実施例の脱細胞化組織はいずれも、比較例の脱細胞化組織に比べて細胞接着数が多く、細胞の誘引効果に優れていた。
実施例8において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ブタの大動脈そのものを使用した以外は、実施例8と同様の操作を行い実施例9の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
実施例8において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ブタの皮膚(真皮を含む)を使用した以外は、実施例8と同様の操作を行い実施例10の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
実施例8において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ブタの心膜を使用した以外は、実施例8と同様の操作を行い実施例11の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
実施例8において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ウシの大動脈を切り開いて採取したシート状の内膜を使用した以外は、実施例8と同様の操作を行い実施例12の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
比較例1において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ブタの大動脈そのものを使用した以外は、比較例1と同様の操作を行い比較例7の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
比較例1において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ブタの皮膚(真皮を含む)を使用した以外は、比較例1と同様の操作を行い比較例8の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
比較例1において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ブタの心膜を使用した以外は、比較例1と同様の操作を行い比較例9の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
比較例1において、ブタの大動脈を切り開いて採取したシート状の内膜(内膜シート)の替わりに、ウシの大動脈を切り開いて採取したシート状の内膜を使用した以外は、比較例1と同様の操作を行い比較例10の脱細胞化組織を得た。得られた脱細胞化組織の脱細胞化DNA比と脱細胞化吸熱量比を、上記方法で算出した。結果を表2に示す。
Claims (2)
- 生体由来組織を脱細胞化した脱細胞化組織であって、
脱細胞化前の生体由来組織に対する脱細胞化組織の、示差走査熱量測定により測定される、乾燥質量あたりの吸熱量の比が0.70以上であることを特徴とする脱細胞化組織。 - 脱細胞化前の生体由来組織に対する脱細胞化組織の、乾燥質量あたりのDNA量の質量比が0.300以下であることを特徴とする請求項1に記載の脱細胞化組織。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211368815.6A CN115554474A (zh) | 2015-02-27 | 2016-02-19 | 脱细胞化组织 |
US15/552,669 US20180028722A1 (en) | 2015-02-27 | 2016-02-19 | Decellularized tissue |
CA2977462A CA2977462A1 (en) | 2015-02-27 | 2016-02-19 | Decellularized tissue |
JP2017502331A JP6666898B2 (ja) | 2015-02-27 | 2016-02-19 | 脱細胞化組織 |
EP16755379.1A EP3263140B1 (en) | 2015-02-27 | 2016-02-19 | Decellularized tissue |
KR1020177020149A KR102501235B1 (ko) | 2015-02-27 | 2016-02-19 | 탈세포화 조직 |
EP20196017.6A EP3782629A1 (en) | 2015-02-27 | 2016-02-19 | Decellularized tissue |
CN201680012049.6A CN107249656A (zh) | 2015-02-27 | 2016-02-19 | 脱细胞化组织 |
HK18104571.9A HK1245159A1 (zh) | 2015-02-27 | 2018-04-09 | 脫細胞化組織 |
US16/713,772 US20200114044A1 (en) | 2015-02-27 | 2019-12-13 | Decellularized tissue |
US16/906,111 US20200324024A1 (en) | 2015-02-27 | 2020-06-19 | Decellularized tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-037992 | 2015-02-27 | ||
JP2015037992 | 2015-02-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/552,669 A-371-Of-International US20180028722A1 (en) | 2015-02-27 | 2016-02-19 | Decellularized tissue |
US16/713,772 Continuation US20200114044A1 (en) | 2015-02-27 | 2019-12-13 | Decellularized tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016136633A1 true WO2016136633A1 (ja) | 2016-09-01 |
Family
ID=56788798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/054911 WO2016136633A1 (ja) | 2015-02-27 | 2016-02-19 | 脱細胞化組織 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20180028722A1 (ja) |
EP (2) | EP3782629A1 (ja) |
JP (1) | JP6666898B2 (ja) |
KR (1) | KR102501235B1 (ja) |
CN (2) | CN115554474A (ja) |
CA (1) | CA2977462A1 (ja) |
HK (1) | HK1245159A1 (ja) |
TW (1) | TWI769132B (ja) |
WO (1) | WO2016136633A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019087880A1 (ja) * | 2017-10-31 | 2019-05-09 | 株式会社Adeka | シート状脱細胞化材料及び同材料を用いる人工血管 |
WO2021029216A1 (ja) * | 2019-08-09 | 2021-02-18 | 国立研究開発法人国立長寿医療研究センター | 象牙質再生用細胞培養物 |
WO2022102739A1 (ja) * | 2020-11-12 | 2022-05-19 | 株式会社Adeka | 脱細胞化組織組成物 |
WO2022270569A1 (ja) | 2021-06-23 | 2022-12-29 | 株式会社Adeka | 脱細胞化細胞構造体 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108144121B (zh) * | 2018-01-23 | 2021-05-14 | 首都医科大学宣武医院 | 一种生物源性小口径组织工程血管的制备方法 |
KR102559788B1 (ko) * | 2022-04-21 | 2023-07-27 | 주식회사 티앤알바이오팹 | 다단계 탈세포화된 조직 매트릭스 및 이의 제조방법 |
KR102559781B1 (ko) * | 2022-04-21 | 2023-07-27 | 주식회사 티앤알바이오팹 | 다단계 탈세포화된 조직 보충재 및 이의 제조방법 |
CN115554472B (zh) * | 2022-09-22 | 2023-08-18 | 舩本诚一 | 一种用于移植的生物组织处理方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063316A1 (ja) * | 2003-12-26 | 2005-07-14 | Cardio Incorporated | 移植可能な生体材料およびその作成方法 |
JP2007301262A (ja) * | 2006-05-15 | 2007-11-22 | Univ Waseda | 移植用生体組織 |
JP2010504093A (ja) * | 2006-09-21 | 2010-02-12 | リージェンプライム カンパニー リミテッド | 細胞由来の細胞外基質膜の製造方法 |
JP2010227246A (ja) * | 2009-03-26 | 2010-10-14 | Tokyo Medical & Dental Univ | 脱細胞化生体組織の調製方法 |
WO2014013241A1 (en) * | 2012-07-18 | 2014-01-23 | Northwick Park Institute For Medical Research Ltd | Implant and method for producing an implant |
WO2014181886A1 (ja) * | 2013-05-07 | 2014-11-13 | 一般財団法人化学及血清療法研究所 | 粒子状脱細胞化組織を含むハイブリッドゲル |
JP2015160039A (ja) * | 2014-02-28 | 2015-09-07 | 国立大学法人 東京医科歯科大学 | 脱細胞組織の製造方法 |
JP2015160040A (ja) * | 2014-02-28 | 2015-09-07 | 株式会社Adeka | 脱細胞組織の製造方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA843751B (en) | 1983-06-10 | 1984-12-24 | University Patents Inc | Body implants of extracellular matrix and means and methods of making and using such implants |
ES2175753T3 (es) | 1997-06-27 | 2002-11-16 | Augustinus Bader | Injerto biosintetico y metodo para su produccion. |
EP1117446B1 (en) | 1998-09-30 | 2004-11-24 | Medtronic, Inc. | Process for reducing mineralization of tissue used in transplantation |
US6376244B1 (en) | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
JP2004094552A (ja) | 2002-08-30 | 2004-03-25 | Sumitomo Chem Co Ltd | 病理組織画像解析方法および病理組織画像解析システム |
JP4092397B2 (ja) * | 2002-09-10 | 2008-05-28 | 国立循環器病センター総長 | 超高静水圧印加による移植用生体組織の処理方法 |
JP3686068B2 (ja) | 2003-12-25 | 2005-08-24 | 佳宏 高見 | 皮膚の分離無細胞化方法、無細胞化真皮マトリックス及びその製造方法並びに無細胞化真皮マトリックスを用いた複合培養皮膚 |
JP2005211480A (ja) | 2004-01-30 | 2005-08-11 | Yoshihiro Takami | 皮膚の分離無細胞化方法、無細胞化真皮マトリックス及びその製造方法並びに無細胞化真皮マトリックスを用いた複合培養皮膚 |
JP2008111530A (ja) * | 2006-10-31 | 2008-05-15 | Sankei Giken:Kk | 管継手 |
JP5331960B2 (ja) | 2007-03-09 | 2013-10-30 | 国立大学法人 東京医科歯科大学 | 脱細胞化軟組織の調製方法、移植片、及び培養部材 |
JP5610268B2 (ja) | 2009-02-25 | 2014-10-22 | 国立大学法人神戸大学 | 高張電解質溶液による生体組織の脱細胞化処理方法 |
EP2467148B1 (en) * | 2009-08-18 | 2016-07-13 | Lifecell Corporation | Method for sterilising dermis |
JP2013042677A (ja) * | 2011-08-22 | 2013-03-04 | Tokyo Medical & Dental Univ | 脱細胞処理液、脱細胞化角膜の調製方法、及び脱細胞化角膜を備える移植片 |
EP2752192B1 (en) * | 2011-09-02 | 2019-06-26 | Adeka Corporation | Method for preparing decellularized tissue product, and graft provided with decellularized tissue product |
GB201215725D0 (en) * | 2012-09-04 | 2012-10-17 | Univ Leeds | Composite connective tissue and bone implants |
JP6248051B2 (ja) * | 2013-01-08 | 2017-12-13 | 一般財団法人化学及血清療法研究所 | 脱細胞化血管シートを用いた人工血管 |
US20160058910A1 (en) * | 2013-05-07 | 2016-03-03 | Natiional University Corporation Tokyo Medical And Dental University | Method for preparing particulate decellularized tissue |
-
2016
- 2016-02-19 WO PCT/JP2016/054911 patent/WO2016136633A1/ja active Application Filing
- 2016-02-19 EP EP20196017.6A patent/EP3782629A1/en active Pending
- 2016-02-19 EP EP16755379.1A patent/EP3263140B1/en active Active
- 2016-02-19 CN CN202211368815.6A patent/CN115554474A/zh active Pending
- 2016-02-19 JP JP2017502331A patent/JP6666898B2/ja active Active
- 2016-02-19 CN CN201680012049.6A patent/CN107249656A/zh active Pending
- 2016-02-19 US US15/552,669 patent/US20180028722A1/en not_active Abandoned
- 2016-02-19 KR KR1020177020149A patent/KR102501235B1/ko active IP Right Grant
- 2016-02-19 CA CA2977462A patent/CA2977462A1/en active Pending
- 2016-02-24 TW TW105105541A patent/TWI769132B/zh active
-
2018
- 2018-04-09 HK HK18104571.9A patent/HK1245159A1/zh unknown
-
2019
- 2019-12-13 US US16/713,772 patent/US20200114044A1/en active Pending
-
2020
- 2020-06-19 US US16/906,111 patent/US20200324024A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063316A1 (ja) * | 2003-12-26 | 2005-07-14 | Cardio Incorporated | 移植可能な生体材料およびその作成方法 |
JP2007301262A (ja) * | 2006-05-15 | 2007-11-22 | Univ Waseda | 移植用生体組織 |
JP2010504093A (ja) * | 2006-09-21 | 2010-02-12 | リージェンプライム カンパニー リミテッド | 細胞由来の細胞外基質膜の製造方法 |
JP2010227246A (ja) * | 2009-03-26 | 2010-10-14 | Tokyo Medical & Dental Univ | 脱細胞化生体組織の調製方法 |
WO2014013241A1 (en) * | 2012-07-18 | 2014-01-23 | Northwick Park Institute For Medical Research Ltd | Implant and method for producing an implant |
WO2014181886A1 (ja) * | 2013-05-07 | 2014-11-13 | 一般財団法人化学及血清療法研究所 | 粒子状脱細胞化組織を含むハイブリッドゲル |
JP2015160039A (ja) * | 2014-02-28 | 2015-09-07 | 国立大学法人 東京医科歯科大学 | 脱細胞組織の製造方法 |
JP2015160040A (ja) * | 2014-02-28 | 2015-09-07 | 株式会社Adeka | 脱細胞組織の製造方法 |
Non-Patent Citations (2)
Title |
---|
NGANGAN. A. V. ET AL.: "Acellularization of embryoid bodies via physical disruption methods", BIOMATERIALS, vol. 30, no. 6, 2009, pages 1143 - 1149, XP025840059, DOI: doi:10.1016/j.biomaterials.2008.11.001 * |
See also references of EP3263140A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019087880A1 (ja) * | 2017-10-31 | 2019-05-09 | 株式会社Adeka | シート状脱細胞化材料及び同材料を用いる人工血管 |
KR20200081355A (ko) * | 2017-10-31 | 2020-07-07 | 가부시키가이샤 아데카 | 시트형 탈세포화 재료 및 동 재료를 사용하는 인공 혈관 |
JPWO2019087880A1 (ja) * | 2017-10-31 | 2020-09-24 | 株式会社Adeka | シート状脱細胞化材料及び同材料を用いる人工血管 |
EP3705141A4 (en) * | 2017-10-31 | 2021-08-18 | Adeka Corporation | LEAF-SHAPED DECELLULARIZED MATERIAL AND ARTIFICIAL BLOOD VESSEL WITH USE OF THE SAID MATERIAL |
AU2018358273B2 (en) * | 2017-10-31 | 2023-11-16 | Adeka Corporation | Sheet-like decellularized material and artificial blood vessel employing said material |
JP7412174B2 (ja) | 2017-10-31 | 2024-01-12 | 株式会社Adeka | シート状脱細胞化材料及び同材料を用いる人工血管 |
KR102700693B1 (ko) | 2017-10-31 | 2024-08-28 | 가부시키가이샤 아데카 | 시트형 탈세포화 재료 및 동 재료를 사용하는 인공 혈관 |
WO2021029216A1 (ja) * | 2019-08-09 | 2021-02-18 | 国立研究開発法人国立長寿医療研究センター | 象牙質再生用細胞培養物 |
JP2021027803A (ja) * | 2019-08-09 | 2021-02-25 | 国立研究開発法人国立長寿医療研究センター | 象牙質再生用細胞培養物 |
WO2022102739A1 (ja) * | 2020-11-12 | 2022-05-19 | 株式会社Adeka | 脱細胞化組織組成物 |
WO2022270569A1 (ja) | 2021-06-23 | 2022-12-29 | 株式会社Adeka | 脱細胞化細胞構造体 |
Also Published As
Publication number | Publication date |
---|---|
JP6666898B2 (ja) | 2020-03-18 |
JPWO2016136633A1 (ja) | 2018-02-22 |
EP3782629A1 (en) | 2021-02-24 |
US20180028722A1 (en) | 2018-02-01 |
US20200114044A1 (en) | 2020-04-16 |
CN107249656A (zh) | 2017-10-13 |
EP3263140A1 (en) | 2018-01-03 |
TWI769132B (zh) | 2022-07-01 |
EP3263140A4 (en) | 2018-10-24 |
EP3263140B1 (en) | 2021-03-31 |
KR20170122178A (ko) | 2017-11-03 |
HK1245159A1 (zh) | 2018-08-24 |
CA2977462A1 (en) | 2016-09-01 |
US20200324024A1 (en) | 2020-10-15 |
CN115554474A (zh) | 2023-01-03 |
KR102501235B1 (ko) | 2023-02-16 |
TW201634689A (zh) | 2016-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016136633A1 (ja) | 脱細胞化組織 | |
US20220073881A1 (en) | Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products | |
JP6271299B2 (ja) | 脱細胞組織の製造方法 | |
JP6793113B2 (ja) | 脱細胞化組織を用いた癒着防止材及び代用生体膜 | |
JP6623333B2 (ja) | 粒子状脱細胞化組織の製造方法 | |
KR20180095913A (ko) | 탈세포화된 태반막 및 이의 제조 방법 및 용도 | |
US11331348B2 (en) | Compositions comprising extracellular matrix of primitive animal species and related methods | |
Park et al. | Preparation of immunogen-reduced and biocompatible extracellular matrices from porcine liver | |
JP2007528755A (ja) | 三次元組織構造体 | |
JP6271298B2 (ja) | 脱細胞組織の製造方法 | |
US20150344842A1 (en) | Method for production of decellularized biological material and the decellularized biological material prepared therefrom | |
CN110740762A (zh) | 移植用脱细胞化材料制造方法及由包含该材料的生物相容性材料组成的移植片组成物 | |
KR102181811B1 (ko) | 조직의 탈세포화 방법 | |
Poornejad | Decellularization and Recellularization Processes for Whole Porcine Kidneys |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16755379 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017502331 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177020149 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2977462 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2016755379 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |